Web Exclusives
Web Exclusives | February 21, 2023
Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | February 21, 2023
A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.
Web Exclusives | February 21, 2023
A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.
Web Exclusives | January 26, 2023
A review of multiple clinical trials in patients with non–small-cell lung cancer and brain metastases finds adagrasib effectively penetrates the central nervous system, resulting in good response rates.
Web Exclusives | January 26, 2023
Sotorasib in a patient with KRAS G12C–mutated lung cancer and brain metastases resolved or shrank brain lesions and improved mental status.
Web Exclusives | January 26, 2023
In patients with non–small-cell lung cancer, broad and rapid genomic profiling are recommended for use at all stages of clinical management to improve patient outcomes.
Web Exclusives | January 26, 2023
Study determines that permanently discontinuing immune checkpoint inhibitors after grade ≥2 immune-related adverse events is an appropriate response for patients with stage IV non–small-cell lung cancer.
Web Exclusives | December 5, 2022
A guide to the departments and people you should be working with to collect the data pertinent to your navigation program.
Web Exclusives | December 5, 2022
Navigators in the Metric Pilot Study increased the number of palliative care referrals through the use of a symptom assessment tool and worked together to improve the assessment process.
Web Exclusives | December 2, 2022
In a recent study, circulating tumor cells were found to act as a precise biomarker in early assessment and therapy monitoring in patients with lung cancer.
Web Exclusives | December 2, 2022
All patient ethnic/racial groups demonstrated improved clinical outcome when experiencing immune-related adverse events while receiving therapy with an immune checkpoint inhibitor, but Hispanic patients appear to derive less benefit.
Web Exclusives | December 2, 2022
Maintaining quality of life and independence was found to be a high priority for patients with non–small-cell lung cancer and should be regularly assessed by the care team.
Web Exclusives | December 2, 2022
Despite advantages for molecular testing for non–small-cell lung cancer, the testing rate remains low, with white patients and female patients having a higher likelihood of undergoing molecular testing.
Web Exclusives | November 2, 2022
In a recent trial of patients with advanced non–small-cell lung cancer, liquid biopsy led to faster molecular results and shortened time to treatment.
Web Exclusives | November 2, 2022
CodeBreak 200 phase 3 trial results demonstrated that sotorasib achieved a more robust survival benefit versus docetaxel in patients with advanced non–small-cell lung cancer harboring KRAS G12C mutation.
Web Exclusives | November 2, 2022
Biomarker testing is the standard of care in advanced non–small-cell lung cancer, but the rate of patients receiving test results prior to initiating treatment is low.
Web Exclusives | November 2, 2022
Study finds that frequencies of mutations commonly found in patients with non–small-cell lung cancer vary among members of 3 racial groups.
Web Exclusives | November 2, 2022
Study of patients with lung adenocarcinoma found that patients with KRAS G12C mutation and high PD-L1 expression benefit more from immunotherapy compared with patients with other KRAS mutations.
Web Exclusives | October 14, 2022
A study in patients with KRAS G12C-mutated non–small-cell lung cancer with brain metastases found adagrasib to demonstrate intracranial activity while being well tolerated.
Web Exclusives | October 14, 2022
Study finds circulating tumor DNA reveals disease recurrence before radiographic evidence in patients with non–small-cell lung cancer.
Web Exclusives | October 14, 2022
Recent study showed that KRAS mutation in patients with non–small-cell lung cancer predicted superior response to first-line immunotherapy.
Web Exclusives | October 14, 2022
Real-world analysis of mutations in non–small-cell lung cancer showed similar frequencies of common KRAS and EGFR variants in Black and White Americans, but higher EGFR G719S variant was seen in Black Americans.
Web Exclusives | September 26, 2022
When clinicians and patients rely on different terminology for the term “cure” in cancer treatment, it can lead to patient dissatisfaction and confusion.
Web Exclusives | September 26, 2022
Next-generation sequencing at initial workup of the patient with advanced non–small-cell lung cancer can shorten time between diagnosis and treatment and may improve survival.
Web Exclusives | September 26, 2022
Recent study found that the use of sotorasib after anti–PD-L1 therapy in patients with NSCLC increased the chance of severe adverse events and liver toxicity.
Web Exclusives | September 26, 2022
Patients with non–small-cell lung cancer with a history of prior radiotherapy before immune checkpoint inhibitor treatment are at increased risk for developing severe pneumonitis.
Web Exclusives | June 28, 2022
Anxiety and depression in patients with advanced lung cancer are associated with poor outcomes when untreated. Radiotherapy, breathlessness, and fatigue are among top predictors of these debilitating conditions.
Web Exclusives | June 28, 2022
Study evaluates factors that may help determine whether a patient with advanced non–small-cell lung cancer may benefit from the use of immune checkpoint inhibitors.
Web Exclusives | June 28, 2022
In patients with non–small-cell lung cancer, KRAS G12C mutation is associated with female sex, smoking, and adenocarcinoma and the risk of development of central nervous system metastasis.
Web Exclusives | June 28, 2022
Analysis reveals factors associated with the development of immune-related adverse events in patients with advanced non–small-cell lung cancer treated with immunotherapy.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512